Cargando…
PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation
Prostate cancer is the leading cancer in North American men. Current pharmacological treatments are limited to anti-androgen strategies and the development of new therapeutic approaches remains a challenge. As a fundamentally new approach, we propose the inhibition of PACE4, a member of the proprote...
Autores principales: | Levesque, Christine, Couture, Frédéric, Kwiatkowska, Anna, Desjardins, Roxane, Guérin, Brigitte, Neugebauer, Witold A., Day, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414146/ https://www.ncbi.nlm.nih.gov/pubmed/25682874 |
Ejemplares similares
-
Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity
por: Couture, Frédéric, et al.
Publicado: (2015) -
Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug
por: Kwiatkowska, Anna, et al.
Publicado: (2019) -
Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model of androgen independent prostate cancer
por: Mekdad, Nawel, et al.
Publicado: (2022) -
The Multi-Leu Peptide
Inhibitor Discriminates Between
PACE4 and Furin And Exhibits Antiproliferative Effects On Prostate
Cancer Cells
por: Levesque, Christine, et al.
Publicado: (2012) -
Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target()
por: Longuespée, Rémi, et al.
Publicado: (2014)